Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study

A retrospective analysis of 100 cases of personalized bacteriophage therapy (BT) for difficult-to-treat infections in 35 hospitals, 29 cities, and 12 countries from 2008 to 2022 reveals that BT has shown general efficacy and can be effective in combination with antibiotics. The most common indications were lower respiratory tract, skin and soft tissue, and bone infections. The study found that eradication was 70% less probable when no concomitant antibiotics were used. However, 15 adverse events were reported, including seven non-serious drug reactions suspected to be linked to BT.